Sativa Investments PLC Reclassification as a Trading Company, Proposed name change & RSM appointed as Auditor

Sativa Investments PLC (NEX: SATI), which joined the NEX Exchange Growth Market in March 2018 as the UK’s first medicinal cannabis investment vehicle, today announced a strategic update ahead of the Company’s announcement of audited results for the year ended 31 December 2018, scheduled for 13 May 2019.

Commenting on these developments, Chief Executive and Founder Geremy Thomas said: “Sativa delivered on its Listing objectives expeditiously and is now into its next phase of becoming a full-spectrum Group covering the key value-add parts of the medicinal cannabis and CBD industries.

“The Group has an exciting future and the team is looking forward to achieving future key milestones including the opening of the Bath Goodbody & Blunt store and the planting of the first seeds at our test and growing facility once Home Office approval is granted.”

Strategic Update

Due to the faster than expected advancement of the UK Medicinal Cannabis regulatory environment, and the evolution in consumer demand for Cannabidiol (CBD) products across Europe, Sativa has amended its strategy to focus more on UK operations, which already include 100% ownership of two UK based businesses, CBD manufacturer, wholesaler and retailer George Botanicals, and PhytoVista Laboratories, an independent testing facility that analyses both the Company’s and third parties’ products and compounds. The Company also has a 60% controlling share in a German subsidiary.

Sativa has announced the opening of its first Goodbody & Blunt retail wellness centre in early summer.

In October 2018, Sativa signed an option over a 7.53 acre site in Wiltshire to allow it to evaluate the commercial viability of developing and owning a large-scale UK growing facility. The Company has since concluded that smart-sourcing of the raw material, to which the Company can then add value through advanced extraction, manufacture, testing, distribution and research of medicinal cannabis and CBD products, will provide greater returns to the Company than growing its own supply. The option, which was acquired at a cost of £85,000, will therefore be allowed to lapse on 1 July 2019.

The Company’s application for a Home Office Research & Development licence to grow medicinal cannabis is proceeding well. This application, if approved, is expected to meet the immediate need to satisfy the Company’s three-year research agreement with King’s College London relating to the impact of cannabinoids on inflammation and respiratory diseases. Subject to the grant of the licence, the Company will grow a limited number of cannabis plant varieties to order at its highly secure test production facility. The Company is planting imminently its second crop of hemp, covered by its low THC growing licence.

Proposed name change

As Sativa has substantially fulfilled the investment strategy set out when it joined the NEX Exchange Growth Market, the Company will now be classified as a trading company, rather than an investment vehicle. The Directors believe that this might broaden the appeal of the equity opportunity to additional institutions and family offices, many of which are precluded from investing in fund-type vehicles.

To reflect this re-classification, the Company intends to change its name to Sativa Group Plc, and a resolution to that effect will be put to shareholders at the forthcoming AGM.

RSM appointed as Auditor

In tandem with its expansion plans, the Company has appointed international audit and advisory firm RSM as the Company’s Auditor, and RSM will be reporting on the Company’s results for the year ended 31 December 2018 which are due to be released on Monday 13 May 2019. The audit team is led by Partner Neil Stephenson.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Sativa Investments plc

    More articles like this

    DirectorsTalk

    CBD as a novel food: the UK’s stance post-Brexit

    The UK FSA’s announcements that it will consider novel food applications for CBD products stands in contrast to the position taken by the European Commission during the summer of 2020, who have currently ‘paused’ novel food

    DirectorsTalk

    What cannabinoids are found in CBD oils?

    CBD oils can be purely made from seeds or they can be a combination of cannabinoids, flavonoids, and terpenes. Every CBD oil is a little bit different, and you will want to make sure you read

    DirectorsTalk

    How the UK CBD industry is thriving in uncertain times

    This year covid-19 has hit hard with far-reaching economic implications for countries around the world. The United Kingdom is no exception as the economy has taken the brunt of the pandemic’s negative effects. However certain markets

    DirectorsTalk

    UK CBD market on a high

    Just when you thought the ‘hype’ around CBD adoption was a passing fad, UK’s nascent CBD market happens to be among the few industries maintaining an upward growth amidst the recent COVID-19 pandemic devastation in the

    DirectorsTalk

    How to integrate CBD oil into your diet

    The internet is awash with information and testimonies on the benefits of CBD oil and the potential that it has in alleviating a number of ailments. Whether or not some of these claims are true is

    DirectorsTalk

    Why should you choose CBD oil?

    Cannabidiol (CBD) is a non-psychoactive yet active chemical component among cannabinoids, a group of compounds found in marijuana plants otherwise known as Cannabis sativa. Conversely, Tetrahydrocannabinol (THC) is the principal psychoactive component that causes an intoxicating

    DirectorsTalk

    A guide to CBD

    What is CBD? CBD – It’s a relatively new product, but how can it benefit you? Most people haven’t even heard of it and yet it’s starting to appear in conversations around sports, food and beauty

    Sativa Group

    Is CBD oil legal in the UK?

    The legal status of CBD in the UK is reflected in many countries worldwide, with the main difference being the levels of THC allowed in the finished product. CBD has seen such a rapid rise to

    Sativa Group

    Sativa Group joins the ACI toxicology study

    As part of the Sativa Group PLC (AQUIS:SATI) ongoing commitment to continually deliver the highest level of regulatory compliance and substantiate ‘CBD you can trust’, the Company has become a member of the Association for the

    Sativa Group

    A comprehensive guide to CBD in the UK

    CBD is being added to products across the retail spectrum from food to make-up. According to claims by the Centre for Medical Cannabis, six million people in the UK have tried CBD, and this year the

    Sativa Group

    A new cannabis wellness era: A history of CBD

    Cannabis Sativa L. has been utilised for a large variety of ailments, industrial applications, and ceremonial uses for millennia. Evidence gathered from significant ancient sites has revealed that the plant was important, and even sacred, in

    Sativa Group

    How CBD can help level up your workout

    With gyms closed and group classes relegated to the online world, at-home workouts are the new normal. Feeling a bit lackluster after months of squats in your living room? Want a new solution so you can

    Sativa Group

    What is CBD? How does it work?

    What is CBD? It’s in everything from beauty products to lattes, but those three letters are thrown around so much that you’d be forgiven for not knowing what CBD is, exactly. More importantly, you might be wondering, is CBD safe?

    Sativa Group

    Sativa Group CSE conditionally approves Sativa Wellness Group

    Sativa Group plc (AQUIS:SATI) has announced that the Canadian Securities Exchange conditionally approved the Listing Application for Sativa Wellness Group Inc. on September 7, combining the operations of Sativa Group PLC and Stillcanna Inc. As previously